Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-glucan recognition proteins (BGRPs) are a family of pattern recognition receptors (PRRs) essential for the innate immune system's ability to detect fungal and certain bacterial pathogens (ResearchGate, 2012; NIH, 2015). Primarily characterized in invertebrates like insects and crustaceans, BGRPs specifically bind to beta-1,3-glucans, which are major structural components of fungal cell walls (NIH, 2010). Upon binding, these proteins trigger critical defense mechanisms, including the prophenoloxidase (proPO) activation system—leading to melanization and encapsulation of pathogens—and the Toll signaling pathway, which induces the production of antimicrobial peptides (Frontiers, 2024; NIH, 2015). In mammals, while direct BGRP homologs are absent, functional counterparts such as Dectin-1 (CLEC7A) and Complement Receptor 3 (CR3) perform analogous roles in sensing fungal infections and modulating immune responses (NIH, 2010; NIH, 2021). BGRPs and their mammalian equivalents are significant therapeutic targets; beta-glucan-based compounds like lentinan and schizophyllan are utilized as biological response modulators to enhance anti-tumor immunity and resistance to infections (NIH, 2021; MDPI, 2021). Additionally, BGRPs are employed in diagnostic assays, such as the Limulus amebocyte lysate (LAL) test, to detect systemic fungal contamination and infections (MDPI, 2021). The study of BGRPs also provides insights into the evolution of innate immunity and the development of novel antifungal strategies (ResearchGate, 2012).
Binding to beta-1,3-glucan motifs on fungal or microbial cell walls, leading to the activation of downstream immune signaling pathways such as the Toll pathway or the prophenoloxidase cascade (NIH, 2015; ResearchGate, 2012).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-glucan recognition protein (BGRP) (BGRP).